TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10427579
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist participation in daily ward rounds, soliciting information, and reviewing charts
Study: 8908382
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.6 g n‐3 fatty acids/day)
Study: 2057245
Drug: Survanta (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survanta (100 mg of phospholipids/kg)
Study: 8950450
Drug: Metallic implants
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metallic implants
Study: 26803913
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day, 250 mg twice daily) added to lipid-lowering therapy
Study: 26803913
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents (control group)
Study: 20489088
Drug: Sequential scanning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scanning mode
Study: 17548203
Drug: Cilostazol (100mg)
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol (100mg) twice daily orally
Study: 10604491
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan once daily
Study: 7828295
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg losartan once daily
Study: 7828295
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg losartan once daily
Study: 7828295
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg losartan once daily
Study: 7828295
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan once daily after 12 weeks
Study: 7828295
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg losartan once daily after 12 weeks
Study: 7828295
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg losartan once daily after 12 weeks
Study: 7828295
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (all doses)
Study: 7049364
Drug: CCNU (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (130 mg/m2 every 6 weeks) + dexamethasone (4‐20 mg daily)
Study: 7049364
Drug: CCNU (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCNU (130 mg/m2 every 6 weeks)
Study: 7049364
Drug: VM‐26 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM‐26 (100 mg/m2) + CCNU (130 mg/m2 every 6 weeks)
Study: 7049364
Drug: Procarbazine (3‐week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procarbazine (3‐week courses of 150 mg/m2/day)
Study: 30892603
Drug: PUVA induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA induction regimen (oral 8-methoxypsoralen followed by UV-A exposure 2 times per week for 12 to 24 weeks)
Study: 30892603
Drug: PUVA maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA maintenance treatment (14 total exposures for 9 months)
Study: 25417709
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral conjugated equine estrogen (oCEE, 0.45 mg)
Study: 25417709
Drug: Weekly transdermal
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly transdermal 17β‐estradiol (tE2, 50 μg)
Study: 23884353
Drug: AMG145 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 70 mg every 2 weeks
Study: 23884353
Drug: AMG145 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 105 mg every 2 weeks
Study: 23884353
Drug: AMG145 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 140 mg every 2 weeks
Study: 23884353
Drug: AMG145 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 280 mg every 4 weeks
Study: 23884353
Drug: AMG145 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 350 mg every 4 weeks
Study: 23884353
Drug: AMG145 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG145 420 mg every 4 weeks
Study: 21091270
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (O) 10 mg once daily, with potential dose increase to 40 mg
Study: 21091270
Drug: Olmesartan (O)
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (O) 10 mg once daily
Study: 21091270
Drug: Ramipril (R)
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril (R) 2.5 mg once daily, with potential dose increase to 10 mg
Study: 17482847
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (n=9)
Study: 17482847
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (n=7)
Study: 9551595
Drug: low-dose or
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose or standard-dose weight-adjusted heparin
Study: 24980
Drug: Fosazepam 60
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosazepam 60 mg
Study: 30981954
Drug: Oxfendazole, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole, administered as multiple oral doses, specific dosage not mentioned.
Study: 15471149
Drug: Biventricular stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular stimulation (cardiac resynchronization therapy)
Study: 7831649
Drug: Fragmin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (low molecular weight heparin) administered subcutaneously once daily at a fixed dose of 200 IU anti-factor Xa/kg
Study: 7831649
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of unfractionated heparin (UFH)
Study: 2956864
Drug: Enoximone 1
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 1 mg/kg
Study: 2956864
Drug: Enoximone 2
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 2 mg/kg
Study: 30187734
Drug: IBA 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBA 0.25 mg L‐1 and kinetin 1 mg L‐1
Study: 30187734
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no added NAA and IBA)
Study: 18803795
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (pill)
Study: 12684357
Drug: Commercial weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial weight loss program (n = 211) consisting of a food plan, activity plan, and cognitive restructuring behavior modification plan, delivered at weekly meetings.
Study: 1549990
Drug: rTPA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA (100 mg over 3 hours)
Study: 3698694
Drug: Incentive spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive spirometry (encouraged by a specialized respiratory physiotherapist to breathe deeply for five minutes hourly, 12 times daily, for three postoperative days)
Study: 20921834
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water (D5W) injection before catheter placement
Study: 19218250
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (Control)
Study: 18514618
Drug: Special oral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special oral nutritional mixture of amino acids (AAs) 4 g twice daily (n = 43)
Study: 16781338
Drug: Topical minocycline
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minocycline (1.0 mg in bioresorbable polyglycolide‐co‐dl‐lactide [PGLA] sustained‐release microspheres)
Study: 16781338
Drug: Topical minocycline
Normalized name: minocycline Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minocycline
Study: 14585449
Drug: Antacid (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (Group 1)
Study: 14585449
Drug: Antacid +
Normalized name: Walgreens Antacid + Anti-Gas Liquid (Mint)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid + Donnatal (Group 2)
Study: 14585449
Drug: Antacid +
Normalized name: Walgreens Antacid + Anti-Gas Liquid (Mint)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid + Donnatal + viscous lidocaine (Group 3)
Study: 9558049
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg/day)
Study: 1578954
Drug: BHAC-DMP +
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHAC-DMP + VCR 0.35 mg/m2 on days 1-4
Study: 1578954
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy of 12 courses
Study: 1578954
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy of 4 courses
Study: 27869485
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (90-min sessions, twice a week for 8 weeks)
Study: 19249048
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of rectal misoprostol
Study: 19249048
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU of intravenous oxytocin
Study: 9523811
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg rocuronium
Study: 9235005
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg atracurium
Study: 9662821
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg orally twice a day for 15-14 days
Study: 9662821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP), vaginal suppositories containing 300 mg of CTP and intravaginal application of 15(2)-30 ml of solution containing 2.0 x 10(6) I.U. of recombinant alpha 2‐interferon
Study: 9662821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant alpha 2‐interferon with complex immunoglobulin preparation (CTP)
Study: 24134550
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Pioglitazone
Study: 10884648
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion at 1 microg. kg(‐1). min(‐1) starting 10 minutes before cardiopulmonary bypass and maintained for 4 hours
Study: 9527094
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion
Study: 9605251
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of antenatal antibiotic therapy
Study: 2873967
Drug: Oral astemizole
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral astemizole (30 mg during the first week, then 10 mg for the rest of the study period)
Study: 2873967
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium cromoglycate (2%, administered 6-times daily intranasally and 4-times daily in the eyes)
Study: 28161387
Drug: Intranasal vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal vasopressin (20IU)
Study: 23451243
Drug: Propranolol (PROP)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PROP) 80 mg administered 60 minutes prior to stress exposure
Study: 21336835
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg, single intramuscular dose)
Study: 21336835
Drug: Syntometrine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntometrine (single intramuscular dose)
Study: 19172538
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) plus methyl-testosterone (1.25 mg) and micronised progesterone (100 mg)
Study: 16246545
Drug: CPT‐11 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 administered at 180 mg/m2 on day 1, by 1‐h infusion (Arm A)
Study: 16246545
Drug: 6‐h sinusoidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐h sinusoidal infusion of CPT‐11 with peak timing at 5:00 a.m. (Arm B)
Study: 14677160
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: actual LPLT (5 minutes, 3 J total dose + exercise)
Study: 14677160
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: actual LPLT (3 minutes, 2 J total dose + exercise)
Study: 2982882
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vincristin, methotrexate, and cyclophosphamide
Study: 2982882
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vincristin, methotrexate, and cyclophosphamide plus systemic immunotherapy with Propionibacterium granulosum strain KP-45
Study: 29059068
Drug: Armeo robotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armeo robotic therapy (12 weeks, 45 min/session, 3 days/week)
Study: 29059068
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (12 weeks)
Study: 22469559
Drug: Bortezomib dose
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib dose intensity
Study: 8141435
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg body weight intravenous infusion over 20 min, followed by 1 mg/kg per hour)
Study: 8141435
Drug: Theophylline at
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline at subtherapeutic concentrations (5 micrograms/ml)
Study: 31296328
Drug: Postoperative rectal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative rectal tube for 5 days (Group A)
Study: 31296328
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative rectal tube (Group B)
Study: 21511276
Drug: LY2216684 6-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2216684 6-18 mg once daily
Study: 17956931
Drug: Minimal Intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Intervention Bibliotherapy Treatment (MIT)
Study: 14615738
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A therapy (administered intramuscularly on days 1, 3, and 7)
Study: 10979640
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily for 12 weeks
Study: 10979640
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg daily for 12 weeks
Study: 10979640
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy + long-acting nitrates, digoxin, aspirin, and furosemide
Study: 8637340
Drug: Subcutaneous standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks
Study: 8637340
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment (control group)
Study: 30865526
Drug: semaglutide 0.5
Normalized name: semaglutide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0.5 mg
Study: 30865526
Drug: semaglutide 1.0
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1.0 mg
Study: 30528641
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (concurrent training: power training + high-intensity interval training, HIIT)
Study: 26376112
Drug: Hi-PRO (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hi-PRO (1.5 g milk protein/100 mL)
Study: 26376112
Drug: Lo-PRO (0.76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo-PRO (0.76 g milk protein/100 mL)
Study: 26376112
Drug: CONT (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONT (0 g milk protein/100 mL)
Study: 25885382
Drug: Gabapentin 10
Normalized name: gabapentin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 10 mg/kg
Study: 9075510
Drug: Paracetamol 20
Normalized name: Paracetamol 20 mg/mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 20 mg/kg
Study: 16928714
Drug: Management pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management pathway to improve early delivery of appropriate antibiotics, implemented using a multifaceted strategy.
Study: 1689512
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse consisting of hydrocortisone, nystatin, tetracycline, and diphenhydramine
Study: 7368106
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 gm the day before operation and 1.2 gm daily for 5 days after operation)
Study: 7368106
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage as metronidazole)
Study: 24956042
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (150-300 mg/day)
Study: 9576164
Drug: Midazolam (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2.0 mg for ≤50 kg, 2.5 mg for 50-80 kg, 3.0 mg for ≥80 kg)
Study: 31969138
Drug: Medication Errors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Errors (ME) observed in patients
Study: 31969138
Drug: Types of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Types of Medication Errors
Study: 31969138
Drug: Drug associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug associated with ME
Study: 30086277
Drug: Clomipramine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 15 mg
Study: 24968543
Drug: Low‐molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐molecular weight heparin (LMWH)
Study: 16336486
Drug: BSW (patient-rated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSW (patient-rated global assessment of treatment benefit)
Study: 16336486
Drug: Patients dissatisfied
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients dissatisfied with treatment
Study: 16336486
Drug: Patients unwilling
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients unwilling to continue treatment
Study: 12587378
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and concurrent chemoradiotherapy
Study: 10099057
Drug: Iscador (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador (twice 0.1 mg and once 2.5 mg)
Study: 10099057
Drug: Iscador (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iscador (2.5 mg)
Study: 2679374
Drug: Pefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (400 mg i.v. or per os every 8 or 12 h for 7 to 180 days)
Study: 2679374
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g i.v. every 8 h or 1 g intramuscularly every 8 h for 7 to 56 days)
Study: 16009588
Drug: Budesonide/formoterol (320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (320/9 microg, two inhalations; total doses 1280/36 microg)
Study: 16009588
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microg x eight inhalations; total doses 1600 microg)
Study: 2238665
Drug: Neomycin and
Normalized name: Neomycin and polymyxin B only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin and erythromycin (1 g each) administered preoperatively to Group B patients.
Study: 2238665
Drug: Cefoxitin or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin or cefotetan (2 g intravenously) administered preoperatively to Group C patients.
Study: 2238665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral and parenteral antibiotics in Group D patients.
Study: 31727428
Drug: Tube shunt
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube shunt (350-mm2 Baerveldt glaucoma implant)
Study: 29477688
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes)
Study: 28785810
Drug: Splint +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splint + paraffin treatment (five consecutive days a week for 3 weeks)
Study: 28785810
Drug: Splint treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint treatment (during the night and day time as much as possible for 3 weeks)
Study: 23749244
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid every 6 months over 3 years
Study: 17943443
Drug: Postmenopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmenopausal hormone therapy